“A a study conducted by the Beckley/Sant Pau Research Programme, and published in the journal Scientific Reports, reveals that certain compounds present in the psychedelic Amazonian brew ayahuasca actually stimulate the birth of new neurons…”
Read More“Ross and Dwyer are at the centre of the country's first clinical trial of psychedelic drugs for treating severe depression in the terminally ill. Within a month, they will begin recruiting 40 depressed and incurable patients in an attempt to relieve their distress with a novel treatment: between one and two 25-milligram doses of synthetic psilocybin, the psychedelic ingredient found in "magic mushrooms", accompanied by intensive psychotherapy sessions…”
Read More“The first formal centre for psychedelic research in the world will launch at Imperial College London today. Funded by more than £3 million from five founding donors, the new Imperial Centre for Psychedelic Research will build on over a decade of pioneering work in this area carried out at Imperial, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression…”
Read More“New research provides evidence that the ritualistic use of the psychedelic drug ayahuasca is not a significant public health concern — and could in fact have potential benefits. The study has been published in the Journal of Psychoactive Drugs…”
Read MoreThere has been a boom in interest in psychedelics, though many people, including licensed providers (LPs), are unfamiliar with the applicable laws and grey areas. Researchers, and advocates must grapple with how to address psychedelics in a way that does not reinforce the harms and injustices of the War on Drugs. We believe the harm reduction movement has much to offer to those who are interested in the current “Psychedelic Renaissance.”…
Read More
